Steven Myers - Caladrius Biosciences Independent Director

CLBSDelisted Stock  USD 0.43  0.39  895.37%   

Director

Mr. Steven S. Myers is an Independent Director of the Company. Steven S. Myers joined the Board in November 2006. He currently serves as Interim Chairman, Lead Independent Director and Chairperson of the Governance Nominating Committee. He also serves on the Audit and Compensation Committees. He graduated from Stanford University with a B.S. in Mathematics. He is a fourtime serial entrepreneur, an Ernst Young Entrepreneur of the Year for Software and Information Services, and a recipient of the California Governors Special Recognition Award. Mr. Myers is a director of several other companies. He has conducted business in a dozen countries in Europe and Asia. His private equity investment company, Dolphin Capital Holdings, Inc. invests in companies with innovative business strategies. Portfolio investments include regenerative medicine, biotechnology, medical devices, applied materials development, alternative energy, distressed debt, and for income real estate. An Administration policy advisor on Cyber Security, he served in 2012 on the Department of Homeland Security Task Force on Cyber Security Resources and briefed thenDHS Secretary Napolitano on the Task Force recommendations. He was recently appointed to a third term on the U.S. State Department Advisory Committee on International Economic Policy, which advises the Secretary of State on foreign policy issues. At the Pacific Council on International Policy he serves on the Board of Directors and is Chairman of their National Security Member Committee. Mr. Myers founded SMA, an Aerospace Defense Industry management consulting firm that over 25 years grew to approximately 100 million in annual revenue and over 800 employees spearheading industrychanging innovations in competing for and managing U.S. Government contracts. During his tenure the company managed more than 360 billion in major program competitions since 2006.
Age 70
Tenure 18 years
Phone908 842-0100
Webwww.caladrius.com

Caladrius Biosciences Management Efficiency

The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (23.84) %, meaning that it generated substantial loss on money invested by shareholders. Caladrius Biosciences' management efficiency ratios could be used to measure how well Caladrius Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 626 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Caladrius Biosciences has a current ratio of 31.73, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Caladrius Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Caladrius Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Caladrius Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Caladrius to invest in growth at high rates of return. When we think about Caladrius Biosciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Bobby OBrienValhi Inc
58
Annie GoodwinGlacier Bancorp
62
David RawlinsonDiscover Financial Services
44
Humberto AlfonsoEastman Chemical
63
Michael ConnorsEastman Chemical
62
George SuttonGlacier Bancorp
72
Jeffrey AroninDiscover Financial Services
53
Dallas HerronGlacier Bancorp
73
Thomas BarryValhi Inc
76
John MurdochGlacier Bancorp
75
Jennifer WongDiscover Financial Services
46
Norman EdelcupValhi Inc
78
Vanessa SutherlandEastman Chemical
48
Kim MinkEastman Chemical
61
Mark SemmensGlacier Bancorp
57
John OwenDiscover Financial Services
63
Lewis KlingEastman Chemical
73
Mary TidlundValhi Inc
63
James BrienEastman Chemical
62
Candace DuncanDiscover Financial Services
67
David RaisbeckEastman Chemical
71
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease andor promote the regeneration of damaged tissue. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Caladrius Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 27 people. Caladrius Biosciences (CLBS) is traded on NASDAQ Exchange in USA and employs 27 people.

Management Performance

Caladrius Biosciences Leadership Team

Elected by the shareholders, the Caladrius Biosciences' board of directors comprises two types of representatives: Caladrius Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caladrius. The board's role is to monitor Caladrius Biosciences' management team and ensure that shareholders' interests are well served. Caladrius Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caladrius Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Mazzo, CEO, Director
Catherine Vaczy, Vice President
Robert Preti, CTO, Sr. VP of Manufacturing and Technical Operations and Director
Eric Wei, Director
Richard Berman, Independent Director
Steven Myers, Independent Director
Cynthia Schwalm, Director
Todd Girolamo, General Counsel
Gregory Brown, Director
Steven Klosk, Independent Director
Douglas Losordo, Chief Medical Officer
Martyn Greenacre, Independent Director
Joseph Talamo, CFO and Sr. VP
Andrew Pecora, Chief Visionary Officer, Director
Peter Traber, Independent Director
Drew Bernstein, Independent Director

Caladrius Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caladrius Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Caladrius Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Caladrius Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Caladrius Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against Caladrius Stock

  0.56MRNA Moderna Earnings Call TomorrowPairCorr
The ability to find closely correlated positions to Caladrius Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Caladrius Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Caladrius Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Caladrius Biosciences to buy it.
The correlation of Caladrius Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Caladrius Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Caladrius Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Caladrius Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Caladrius Biosciences information on this page should be used as a complementary analysis to other Caladrius Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Consideration for investing in Caladrius Stock

If you are still planning to invest in Caladrius Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Caladrius Biosciences' history and understand the potential risks before investing.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
CEOs Directory
Screen CEOs from public companies around the world